Navigation Links
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
Date:2/20/2008

l succinate extended-release tablets and GlaxoSmithKline's sales of Wellbutrin XLP(R) 150mg.

Generic segment gross margin increased from 30 percent in 2006 to 39 percent in 2007, due to the increase in other revenue, improved product mix and enhanced operational efficiencies.

During 2007, Watson submitted 21 ANDAs with the U.S. Food and Drug Administration (FDA). Watson currently has approximately 60 ANDAs on file with the FDA.

Brand Segment Information

Three Months Ended Twelve Months Ended

December 31, December 31,

(Unaudited; $ in thousands) 2007 2006 2007 2006

Brand Segment Contribution

Product sales $94,106 $97,239 $375,202 $354,070

Other revenue 15,232 9,743 53,520 15,402

Net revenue 109,338 106,982 428,722 369,472

Cost of sales 25,814 27,595 99,913 92,184

Gross profit 83,524 79,387 328,809 277,288

Gross margin 76.4% 74.2% 76.7% 75.0%

Research and development 10,435 14,021 42,367 47,472

Selling and marketing 28,664 27,071 108,061 112,258

Segment contribution $44,425 $38,295 $178,381 $117,558

Segment margin 40.6% 35.8% 41.6% 31.8%

Brand product sales for the fourth quarter of 2007 decreased 3 percent or $3.1 million to $94.1 million, primarily due to lower sales of INFeD(R) and Ferrlecit(R). Other revenue increased $5.5 million to $15.2 million, due to increased revenue from the co-promotion of AndroGel(R) and other promoted products.

Gross margin for the Brand segment increased from 74 percent in the fourth quarter 2006 to 76 percent in
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Watson Receives FDA Approval for Generic Accuneb(R)
4. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
5. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
6. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
7. Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA Seal Of Approval
8. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar and Report Full Year 2007 Financial Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. Keryx Biopharmaceuticals Announces Additions to Management Team
11. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Neurotrope, Inc. (OTCQB: ... conference call to provide an update on Company ... daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) or ... cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference replay ... through September 2, 2014 at (888) 203-1112 (U.S. ...
(Date:8/20/2014)... Not long ago, it was more or ... late in the development cycle – even after the ... suggest that, like many things GxP, expectations for early ... multiple drug sponsors have been required by authorities to ... phase I/II. It’s not only clinical trial material containers ...
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... Oxide Fuel Cells (SOFCs) - Global Strategic Business Report" ... the worldwide markets for Solid Oxide Fuel Cells (SOFCs) in ... US, Canada , Europe ... Annual estimates and forecasts are provided for the period 2012 ...
Breaking Biology Technology:Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2
... YORK, March 21, 2011 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, ... "AOBO"), a pharmaceutical company dedicated to improving health through ... of prescription and over the counter ("OTC") products, announced ... 15, 2010, that its board of directors authorized a ...
... Md., March 21, 2011 United Therapeutics Corporation ... enrollment in its FREEDOM-C(2) registration trial was completed ... a 16-week, multi-center, international, double-blind, randomized, placebo-controlled study ... diethanolamine (UT-15C) in pulmonary arterial hypertension (PAH) patients ...
... Recent events in Japan have caused the world to ... be a cause for concern – especially if radiation ... proliferating cells of the body. Cells of the hematopoietic ... two such cell types. Damage to these cells initiates ...
Cached Biology Technology:American Oriental Bioengineering Announces US$20 Million Share Repurchase Program 2United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial 2Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 2Existing Radiation Countermeasures Inadequate! Development of Rx100 Promises Change! 3
(Date:8/20/2014)... Bay Area Lyme Foundation, which aims to make Lyme ... new research published in an upcoming issue of the ... . The findings show that ticks that carry ... year, making the threat of Lyme disease year-round. The ... Public Health (CDPH) Vector-borne Disease Section and University of ...
(Date:8/20/2014)... suffered concussions ready to return to action? A new ... athletes who head back on the field with medical ... their abilities to simultaneously walk and do simple mental ... their balance and/or altered walking speed, was found in ... returned to activity in less than a month. Seven ...
(Date:8/20/2014)... During the past few years, Virginia Tech,s Wu Feng ... Microsoft grant from the "Computing in the Cloud" program, ... a $6 million award from the Air Force on ... from NSF and the National Institutes of Health on ... wove together the "parallel computing" aspects from each grant, ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4
... Even healthy pregnant women can be at risk for ... Reserve University began to understand which bacteria from the 700 ... health problem of preterm and stillbirths. Yiping Han ... Dental Medicine led the study, which found several new bacteria ...
... laboratories, two Dartmouth biologists have performed one of the largest ... population. Their results, published online on May 9 by the ... more important than predation by birds and snakes when it ... Tennyson wrote that nature is ,red in tooth and claw, ...
... May 7, 2010 In findings that advance scientists, ... from The Scripps Research Institute has shed light on a ... other lysosomal storage diseases. The findings were published in ... Biology on May 9, 2010. "This study is ...
Cached Biology News:Even healthy pregnant women need to worry about oral bacteria 2Researchers use entire islands in the Bahamas to test survival of the fittest 2Scripps research scientists shed light on potential treatment for Gaucher's disease 2Scripps research scientists shed light on potential treatment for Gaucher's disease 3Scripps research scientists shed light on potential treatment for Gaucher's disease 4
... The Yeast Whole Genome ChIP-on-chip Microarray ... of yeast (S. cerevisiae) DNA binding ... with Agilent DNA microarrays. This set ... data with greater true binding events ...
... DTT White solid. ... Purity: ≥99% by titration. ... Absorbance: (100 mM, 280 nm):≤0.05. ... or H 2 O. RTECS ...
... pombe Whole Genome ChIP-on-chip Microarray is ... yeast (S. pombe) DNA binding proteins ... Agilent DNA microarrays. This set delivers ... with greater true binding events and ...
... The recent sequencing of Salmonella genomes ... enterica Typhimurium ORFmer PCR* primer pairs. The ... of a single chromosome (4,857,432 bp; 4,440 ... 107 ORFs). These ORFmers from Sigma-Genosys have ...
Biology Products: